HiberCell is at the forefront of developing innovative cancer therapies that specifically target the mechanisms of adaptive stress in tumors, which are often responsible for treatment resistance, relapse, and metastasis. The company focuses on exploiting stress-driven vulnerabilities in cancer cells through a range of therapeutic candidates. Notably, HC-7366 is designed to activate the General Control Nonderepressible 2 (GCN2) kinase, a critical component of the Integrated Stress Response (ISR) pathway, which can induce apoptosis in cancer cells when hyperactivated. Conversely, HC-5404 aims to inhibit the PKR-like Endoplasmic Reticulum Kinase (PERK), another key player in the Unfolded Protein Response (UPR), thereby disrupting the survival mechanisms that cancer cells utilize to withstand treatment.

In addition to these small molecule candidates, HiberCell is also advancing odetiglucan, which modulates tumor-immune interactions to enhance anti-cancer immune responses. This therapeutic approach is designed to reprogram the tumor microenvironment, making it more conducive to immune attack. HiberCell's strategy encompasses a dual approach of either inhibiting or activating stress response pathways, thereby addressing the complexities of cancer biology and aiming to improve patient outcomes in the face of treatment resistance and relapse.

United States

HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both completing Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently in Phase 2 clinical development, modulates the anti-tumor innate immune response.

HiberCell

Company Details